Nephrotoxicity as a cause of acute kidney injury (AKI) induced by cisplatin (CP), limits its usefulness as an anticancer agent. Diminazene, an angiotensin converting enzyme 2 activator, exhibited renoprotective properties on rat models of kidney diseases. This research aims to investigate the salutary effect of diminazene in comparison with lisinopril or valsartan in CP-induced AKI. The first and second groups of rats received oral vehicle (distilled water) for 9 days, and saline injection or intraperitoneal CP (6 mg/kg) on day 6, respectively. Third, fourth, and fifth groups received intraperitoneal injections of CP on day 6 and diminazene (15 mg/kg/day, orally), lisinopril (10 mg/kg/day, orally), or valsartan (30 mg/kg/day, orally), for 9 days, respectively. 24h after the last day of treatment, blood and kidneys were removed under anesthesia for biochemical and histopathological examination. Urine during the last 24 h before sacrificing the rats was also collected. CP significantly increased plasma urea, creatinine, neutrophil gelatinase-associated lipocalin, calcium, phosphorus, and uric acid. It also increased urinary albumin/creatinine ratio, N-Acetyl-beta-D-Glucosaminidase/creatinine ratio, and reduced creatinine clearance, as well the plasma concentrations of inflammatory cytokines [plasma tumor necrosis factor-alpha, and interleukin-1beta], and significantly reduced antioxidant indices [catalase, glutathione reductase , and superoxide dismutase]. Histopathologically, CP treatment caused necrosis of renal tubules, tubular casts, shrunken glomeruli, and increased renal fibrosis. Diminazine, lisinopril, and valsartan ameliorated CP-induced biochemical and histopathological changes to a similar extent. The salutary effect of the three drugs used is, at least partially, due to their anti-inflammatory and antioxidant effects. Keywords: Cisplatin, Diminazene, ACE2 activator, Lisinopril, Valsartan, Acute kidney injury.

Department of Pharmacology and Clinical Pharmacy College of Medicine and Health Sciences Sultan Qaboos University Al Khod Oman

Zobrazit více v PubMed

Nurul RA, Norhashima AR, Faizah O, Siti BB, Farida H, Seong LT. Protective role of natural products in cisplatin-induced nephrotoxicity. Med Chem. 2019;19:1134–1143. doi: 10.2174/1389557519666190320124438. PubMed DOI

Perše M, Večerić-Haler Ž. Cisplatin-induced rodent model of kidney injury: characteristics and challenges. Biomed Res Int. 2018;2018:1462802. doi: 10.1155/2018/1462802. PubMed DOI PMC

Tang C, Livingston MJ, Safirstein R, Dong Z. Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat Rev Nephrol. 2023;19:53–72. doi: 10.1038/s41581-022-00631-7. PubMed DOI

Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol. 2016;310:H137–52. doi: 10.1152/ajpheart.00618.2015. PubMed DOI PMC

Achkar TM, McCullough PA, Sutton MG. The renin-angiotensin system and COVID-19: Implications for renal involvement. Kidney. 2022;3:173–180.

Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S. ACE Inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3–5: A network meta-analysis of randomised clinical trials. Drugs. 2020;80:797–811. doi: 10.1007/s40265-020-01290-3. PubMed DOI PMC

Hill RD, Vaidya PN. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2022. Angiotensin II Receptor Blockers (ARB) https://www.ncbi.nlm.nih.gov/books/NBK537027/ PubMed

Velkoska E, Patel SK, Burrell LM. Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation. Curr Opin Nephrol Hypertens. 2016;25:384–95. doi: 10.1097/MNH.0000000000000254. PubMed DOI

Haber PK, Ye M, Wysocki J, Maier C, Haque SK, Batlle D. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension. 2014;63:774–782. doi: 10.1161/HYPERTENSIONAHA.113.02856. PubMed DOI PMC

Abdelrahman AM, Ali BH, Ali H, Manoj P, Al-Suleimani Y. The effect of diminazene, an angiotensin-converting enzyme 2 activator, on adenine-induced chronic kidney disease in rats. Fundam Clin Pharmacol. 2023;37:235–244. doi: 10.1111/fcp.12845. PubMed DOI

Goru SK, Kadakol A, Malek V, Pandey A, Sharma N, Gaikwad AB. Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes. Br J Pharmacol. 2017;174:3118–3130. doi: 10.1111/bph.13946. PubMed DOI PMC

Lassila M, Finckenberg P, Pere AK, Krogerus L, Ahonen J, Vapaatalo H, Nurminen ML. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br J Pharmacol. 2000;130:1339–1347. doi: 10.1038/sj.bjp.0703422. PubMed DOI PMC

Ali BH, Karaca T, Al Suleimani Y, Al Za'abi M, Al Kalbani J, Ashique M, Nemmar A. The effect of swimming exercise on adenine-induced kidney disease in rats, and the influence of curcumin or lisinopril thereon. PLoS One. 2017;12:e0176316. doi: 10.1371/journal.pone.0176316. PubMed DOI PMC

Ali BH, Za'abi MA, Karaca T, Suleimani YA, Balushi KA, Manoj P, Ashique M, Nemmar A. Potassium bromate-induced kidney damage in rats and the effect of gum acacia thereon. Am J Transl Res. 2018;10:126–137. PubMed PMC

Al Suleimani YM, Abdelrahman AM, Karaca T, Manoj P, Ashique M, Nemmar A, Ali BH. The effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on gentamicin nephrotoxicity in mice. Biomed Pharmacother. 2018;97:1102–1108. doi: 10.1016/j.biopha.2017.10.107. PubMed DOI

Ali BH, Al-Salam S, Al Husseini IS, Al-Lawati I, Waly M, Yasin J, Fahim M, Nemmar A. Abrogation of cisplatin-induced nephrotoxicity by emodin in rats. Fundam Clin Pharmacol. 2013;27:192–200. doi: 10.1111/j.1472-8206.2011.01003.x. PubMed DOI

Manni ML, Czajka CA, Oury TD, Gilbert TW. Extracellular matrix powder protects against bleomycin-induced pulmonary fibrosis. Tissue Eng Part A. 2011;17:2795–2804. doi: 10.1089/ten.tea.2011.0023. PubMed DOI PMC

Lu Z, Wu D, Wan Z, Zhang H, Du Y, Wang G. Diminazene aceturate mitigates cardiomyopathy by interfering with the renin-angiotensin system in a septic rat model. BMC Pharmacol Toxicol. 2022;23:44. doi: 10.1186/s40360-022-00584-4. PubMed DOI PMC

Zhang Y, Liu J, Luo JY, et al. Upregulation of angiotensin (1-7)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes. Antioxid Redox Signal. 2015;23:880–892. doi: 10.1089/ars.2014.6070. PubMed DOI PMC

Gjymishka A, Kulemina LV, Shenoy V, Katovich MJ, Ostrov DA, Raizada MK. Diminazene Aceturate Is an ACE2 Activator and a Novel Antihypertensive Drug. FASEB J. 2010;24(Suppl 1):1032.3. doi: 10.1096/fasebj.24.1_supplement.1032.3. DOI

Shenoy V, Gjymishka A, Jarajapu YP, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013;187:648–657. doi: 10.1164/rccm.201205-0880OC. PubMed DOI PMC

Singh N, Joshi S, Guo L, et al. ACE2/Ang-(1-7)/mas axis stimulates vascular repair-relevant functions of CD34+ cells. Am J Physiol Heart Circ Physiol. 2015;309:H1697–H1707. doi: 10.1152/ajpheart.00854.2014. PubMed DOI PMC

Velkoska E, Patel SK, Griggs K, Pickering RJ, Tikellis C, Burrell LM. Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 Activity in Rats with Subtotal Nephrectomy. PLoS ONE. 2015;10:e0118758–e0118758. doi: 10.1371/journal.pone.0118758. PubMed DOI PMC

Goru SK, Kadakol A, Malek V, Pandey A, Sharma N, Gaikwad AB. Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of Type 1 Diabetes. Br J Pharmacol. 2017;174:3118–3130. doi: 10.1111/bph.13946. PubMed DOI PMC

Asaad GF, Hassan A, Mostafa RE. Anti-oxidant impact of Lisinopril and Enalapril against acute kidney injury induced by doxorubicin in male Wistar rats: involvement of kidney injury molecule-1. Heliyon. 2021;15:e05985. doi: 10.1016/j.heliyon.2021.e05985. PubMed DOI PMC

Esmaeeli A, Ebrahimi F, Tanha K, Assadi M, Seyedabadi M. Low-dose angiotensin AT1 receptor β-arrestin-biased ligand, TRV027, protects against cisplatin-induced nephrotoxicity. Pharmacol Rep. 2020;72:1676–1684. doi: 10.1007/s43440-020-00172-5. PubMed DOI

Fang CY, Lou DY, Zhou LQ, Wang JC, Yang B, He QJ, Wang JJ, Weng QJ. Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol Sin. 2021;42:1951–1969. doi: 10.1038/s41401-021-00620-9. PubMed DOI PMC

Shahid F, Farooqui Z, Khan F. Cisplatin-induced gastrointestinal toxicity: An update on possible mechanisms and on available gastroprotective strategies. Eur J Pharmacol. 2018;827:49–57. doi: 10.1016/j.ejphar.2018.03.009. PubMed DOI

Ali BH, Al Salam S, Al Suleimani Y, Al Za'abi M, Ashique M, Manoj P, Sudhadevi M, Al Tobi M, Nemmar A. Ameliorative effect of sesamin in cisplatin-induced nephrotoxicity in rats by suppressing inflammation, oxidative/nitrosative stress, and cellular damage. Physiol Res. 2020;69:61–72. doi: 10.33549/physiolres.934142. PubMed DOI PMC

Ali BH, Abdelrahman A, Al Suleimani Y, Manoj P, Ali H, Nemmar A, Al Za'abi M. Effect of concomitant treatment of curcumin and melatonin on cisplatin-induced nephrotoxicity in rats. Biomed Pharmacother. 2020;131:110761. doi: 10.1016/j.biopha.2020.110761. PubMed DOI

Baldissera MD, Gonçalves RA, Sagrillo MR, Grando TH, Ritter CS, Grotto FS, Brum GF, da Luz SC, Silveira SO, Fausto VP, Boligon AA, Vaucher RA, Stefani LM, da Silva AS, Souza CF, Monteiro SG. Effects of treatment with the anti-parasitic drug diminazene aceturate on antioxidant enzymes in rat liver and kidney. Naunyn Schmiedebergs Arch Pharmacol. 2016;389:429–438. doi: 10.1007/s00210-016-1212-z. PubMed DOI